Delayed
Hong Kong S.E.
11:59:19 2024-05-19 pm EDT
|
5-day change
|
1st Jan Change
|
12.08
HKD
|
-2.42%
|
|
+1.17%
|
-39.17%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
4,262
|
2,842
|
9,299
|
6,731
|
5,400
|
3,371
|
-
|
-
|
Enterprise Value (EV)
1 |
4,262
|
2,842
|
8,055
|
5,828
|
5,400
|
2,530
|
2,707
|
2,688
|
P/E ratio
|
-43.4
x
|
-13.5
x
|
-25.8
x
|
-29.4
x
|
-56.1
x
|
-33.5
x
|
62.9
x
|
10.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.6
x
|
7.27
x
|
18.2
x
|
10.8
x
|
6.43
x
|
2.66
x
|
1.76
x
|
1.22
x
|
EV / Revenue
|
15.6
x
|
7.27
x
|
15.8
x
|
9.31
x
|
6.43
x
|
2
x
|
1.42
x
|
0.97
x
|
EV / EBITDA
|
-42.7
x
|
-16.4
x
|
-25.4
x
|
-15.6
x
|
-16
x
|
-11.9
x
|
42.6
x
|
6.78
x
|
EV / FCF
|
-33.1
x
|
-10.4
x
|
-29.4
x
|
-17.2
x
|
-
|
-8.85
x
|
-27.8
x
|
-49.1
x
|
FCF Yield
|
-3.02%
|
-9.61%
|
-3.4%
|
-5.81%
|
-
|
-11.3%
|
-3.59%
|
-2.04%
|
Price to Book
|
-
|
3.15
x
|
10.5
x
|
6.65
x
|
-
|
2.62
x
|
2.82
x
|
2.12
x
|
Nbr of stocks (in thousands)
|
1,875,939
|
1,953,283
|
2,101,341
|
2,115,207
|
2,123,163
|
2,124,053
|
-
|
-
|
Reference price
2 |
2.272
|
1.455
|
4.425
|
3.182
|
2.543
|
1.587
|
1.587
|
1.587
|
Announcement Date
|
3/27/20
|
3/26/21
|
3/20/22
|
3/30/23
|
3/10/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
273.4
|
390.8
|
511.1
|
625.7
|
839.5
|
1,267
|
1,912
|
2,759
|
EBITDA
1 |
-99.94
|
-173.6
|
-317.3
|
-372.6
|
-337.1
|
-213.2
|
63.52
|
396.5
|
EBIT
1 |
-119.1
|
-203.9
|
-359.7
|
-436.8
|
-411
|
-256.3
|
-16.51
|
470.9
|
Operating Margin
|
-43.57%
|
-52.17%
|
-70.38%
|
-69.81%
|
-48.96%
|
-20.24%
|
-0.86%
|
17.07%
|
Earnings before Tax (EBT)
1 |
-113.7
|
-281.9
|
-496.4
|
-431.7
|
-351
|
-252.4
|
30.94
|
616.9
|
Net income
1 |
-96.91
|
-204.9
|
-347.9
|
-226.9
|
-95.48
|
-110.9
|
36.09
|
317.9
|
Net margin
|
-35.45%
|
-52.44%
|
-68.07%
|
-36.26%
|
-11.37%
|
-8.75%
|
1.89%
|
11.52%
|
EPS
2 |
-0.0523
|
-0.1078
|
-0.1713
|
-0.1082
|
-0.0453
|
-0.0474
|
0.0252
|
0.1489
|
Free Cash Flow
1 |
-128.6
|
-273
|
-274.2
|
-338.7
|
-
|
-285.8
|
-97.25
|
-54.73
|
FCF margin
|
-47.06%
|
-69.85%
|
-53.65%
|
-54.13%
|
-
|
-22.57%
|
-5.09%
|
-1.98%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/20
|
3/26/21
|
3/20/22
|
3/30/23
|
3/10/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
-
|
-
|
-
|
281.5
|
391.3
|
448.2
|
547.7
|
699.4
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-
|
-
|
-220.2
|
-
|
-125.9
|
-177.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-56.27%
|
-
|
-22.98%
|
-25.42%
|
Earnings before Tax (EBT)
|
-
|
-123.9
|
-
|
-346.2
|
-
|
-
|
-
|
-
|
Net income
|
-113.1
|
-91.85
|
-91.12
|
-256.7
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-91.21%
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0601
|
-
|
-0.0461
|
-
|
-
|
-
|
-0.0100
|
-0.0300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/30/20
|
3/26/21
|
8/23/21
|
3/20/22
|
9/26/23
|
3/10/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
1,245
|
903
|
-
|
840
|
664
|
682
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-129
|
-273
|
-274
|
-339
|
-
|
-286
|
-97.3
|
-54.7
|
ROE (net income / shareholders' equity)
|
-22.5%
|
-31.9%
|
-18.7%
|
-16.3%
|
-
|
-9.49%
|
-0.75%
|
16.3%
|
ROA (Net income/ Total Assets)
|
-
|
-17.5%
|
-9.08%
|
-7.02%
|
-
|
-2.94%
|
1.6%
|
5.3%
|
Assets
1 |
-
|
1,168
|
3,833
|
3,232
|
-
|
3,767
|
2,256
|
5,995
|
Book Value Per Share
2 |
-
|
0.4600
|
0.4200
|
0.4800
|
-
|
0.6100
|
0.5600
|
0.7500
|
Cash Flow per Share
2 |
-
|
-
|
-0.0700
|
-0.0600
|
-
|
-0.0800
|
0.0300
|
0.4700
|
Capex
1 |
-
|
122
|
137
|
218
|
-
|
173
|
202
|
239
|
Capex / Sales
|
-
|
31.19%
|
26.89%
|
34.91%
|
-
|
13.69%
|
10.56%
|
8.67%
|
Announcement Date
|
3/27/20
|
3/26/21
|
3/20/22
|
3/30/23
|
3/10/24
|
-
|
-
|
-
|
Last Close Price
1.587
USD Average target price
3.554
USD Spread / Average Target +123.99% Consensus |
1st Jan change
|
Capi.
|
---|
| -39.17% | 3.37B | | +33.63% | 50.93B | | -0.09% | 42.12B | | +49.62% | 42.05B | | -4.96% | 29.18B | | +11.18% | 26.02B | | -21.95% | 18.9B | | +8.61% | 13.21B | | +24.73% | 12.17B | | +28.31% | 12.16B |
Other Biotechnology & Medical Research
|